Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma
Abstract Background Known as solid tumors of intermediate malignant potential, most inflammatory myofibroblastic tumors (IMTs) are treatable as long as the tumor is en-bloc resected. However, in some cases, the tumors have recurred and grown rapidly after successful surgery. Some of these tumors wer...
Main Authors: | Quan Jiang, Han-Xing Tong, Ying-Yong Hou, Yong Zhang, Jing-Lei Li, Yu-Hong Zhou, Jing Xu, Jiong-Yuan Wang, Wei-Qi Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-05-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-017-0647-8 |
Similar Items
-
Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib
by: Mengmeng Li, et al.
Published: (2023-03-01) -
Mediastinal epithelioid inflammatory myofibroblastic sarcoma with the EML4‐ALK fusion: A case report and literature review
by: Tingyu Pan, et al.
Published: (2024-01-01) -
Epithelioid inflammatory myofibroblastic sarcoma – A rare case report
by: Dona Maria George, et al.
Published: (2024-03-01) -
Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
by: Zhan Wang, et al.
Published: (2022-02-01) -
Inflammatory Myofibroblastic Tumour: State of the Art
by: Louis Gros, et al.
Published: (2022-07-01)